Abstract:Objective To investigate the efficacy and safety of the cetuximab combined with chemotherapy for patients with metastasis from colorectal cancer whose K-Ras status were wild type and explore the factors that may affect the efficacy and prognosis. Methods Retrospectively collected the clinical data of 90 patients with metastasis from colorectal cancer whose K-Ras status were wild type. Cetuximab 400mg/m2 was intravenously given at first dose and maintenance at 250mg/m2 every week or 500mg/m2 every two weeks. Combined chemotherapy regimen included, irinotecan-based chemotherapy(FOLFIRI or XELIRI or irinotecan monotherapy), oxaliplatin-based chemotherapy( FOLFOX or XELOX) ,other regimens, such as 5-FU/leucovorin or capecitabine monotherapy. The ef-ficacy and safety of each line of chemotherapy was summarized and assessed, and the relationship between clinicopathology features, treatment characteristics and efficacy, explore the factors associated with prognosis were analyzed retrospectively. Results The median duration treatment of cetuximab was 16 weeks( 6-44 weeks) . And in all patients the objective response rate( ORR) was 45?6%,and the disease control rate( DCR) was 87?8%. The DCR in first line treatment was 51?6% better than in second line, whose was 40?0%, and the DCR in third line was 18?2%. The age, location of primary tumor, treatment time of cetuximab might affect the efficacy fo cetux- imab plus chemotherapy. In the 90 patients, recurrent metastases were occurred in 82 cases( 91?1%) and death in 60 cases( 66?7%) . The median PFS( mPFS) was 7?8 months and median OS( mOS) was 22?5 months. In the first line treatment of cetuximab plus chemo-therapy, mPFS was 9?1 months and mOS was 27?6 months. In second line treatment mPFS was 7?7 months and mOS was 14?5 month. in third line mPFS was 2?9 months and mOS was 6?7 months. Univariate survival analysis showed that the location of primary tumor, early tumor response and treatment time of cetuximab were related to PFS and OS of the patients, and the metastasis scope was related to the OS of patients. Using the Cox multivariate hazards model to analysis the clinicopathological factors, which showed that the loca-tion of primary tumor and early tumor response were the independent risk factors affecting the PFS of patients, the metastasis scope was the independent risk factor affecting the OS of patients. The most common adverse reaction related to cetuximab is acne-like rash, the side effects associated with chemotherapy mainly were diarrhea, nausea, vomiting, bone marrow suppression. After symptomatic treat-ment, patients can tolerate. Conclusion Cetuximab combined chemotherapy in each line treatment of patients with metastases from colorectal cancer can get great efficacy, and the adverse reactions can be tolerated. The location of primary tumor might be the predic-tors of the efficacy, and it is also associated with the prognosis of the patients. As ETS Shows that early tumor response could be one of the outcome indicators of mCRC.

Comparison of HER2 Overexpression with Total Her2 Mutation on Resistance of EGFR-targeted Therapy in Ras Wild-Type Mcrc Patients.

A Study of Gene Variation in All-RAS Wild-Type Metastatic Colorectal Cancer and Its Correlation with Cetuximab.

Identification and Prognostic Analysis of the Cetuximab Resistance-Related Gene REV1 in RAS Wild-Type Metastatic Colorectal Cancer.

Efficacy analysis of cetuximab plus chemotherapy for K-Ras wild-type colorectal cancer with metastases

Efficacy of Cetuximab-Based Chemotherapy in Metastatic Colorectal Cancer According to RAS and BRAF Mutation Subgroups: A Meta-Analysis

Combined Analysis Of Egfr And Pten Status In Patients With Kras Wild-Type Metastatic Colorectal Cancer

K-ras status and efficacy of cetuximab-containing regimen in the treatment of patients with metastatic colorectal cancer

P1.03-045 HER-2 Mutation is Not a Prognostic Factor Treated with First-Line Chemotherapy in NSCLC Patients

HER2 Positivity As a Biomarker for Poor Prognosis and Unresponsiveness to Anti-Egfr Therapy in Colorectal Cancer

Impact Ofkrasmutation and PTEN Expression on Cetuximab-Treated Colorectal Cancer

[Effect of KRAS Mutation on Efficacy of Cetuximab Combined with Chemotherapy in Advanced Colorectal Cancer Patients].

Survival Analysis of Cetuximab Combined with Chemotherapy for Advanced Colorectal Cancer and Effect of KRAS on Treatment

Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients

Patients with RAS Wild-Type Right-Sided Unresectable Liver-Confined Mcrc Also Benefit from Cetuximab Plus Chemotherapy in First-Line Treatment

Molecular characterization of metastatic colorectal cancer (mCRC) in patients (pts) treated with cetuximab and pembrolizumab.

Chemotherapeutic Effectiveness of Combining Cetuximab for Metastatic Colorectal Cancer Treatment: A System Review and Meta-Analysis

Additional Biomarkers Beyond RAS That Impact the Efficacy of Cetuximab Plus Chemotherapy in Mcrc: A Retrospective Biomarker Analysis

Standard Chemotherapy with Cetuximab for Treatment of Colorectal Cancer

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies

Right- and Left-Sided Colorectal Cancers Respond Differently to Cetuximab

Efficacy Of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy And Its Effects On K-Ras Mutations In Advanced Colorectal Cancer